Array ( [a_id] => 352606 [c_id] => 35674 [r_id] => 894 [rr_id] => 894 [m_id] => 1 [s_id] => 25646 [id_id] => 0 [v_id] => 0 [loc_id] => 0 [ft_id] => 0 [a_classification] => news [a_layout] => 1 [a_headline] => XenoPort's Psoriasis Drug Shows Higher Side Effects; Shares Fall [a_sheadline] => XenoPort's Psoriasis Drug Shows Higher Side Effects [a_slug] => xenoports-psoriasis-drug-shows-higher-side-effects-shares-fall-352606 [a_subheadline] => [a_summary] => The success of XenoPort's psoriasis drug is being overshadowed by its severe gastrointestinal side effects. [a_article] =>
(Reuters) - XenoPort Inc's psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study.
The company's shares, which rose as much as 19 percent premarket, fell sharply in regular trading after the company said on a conference call that a third of its patients in the study dropped out due to the side effects.
During the trial of the drug, XP23829, in patients suffering from the chronic skin disease, adverse events related to diarrhea were 22-40 percent in the drug group, compared with 15 percent in the placebo group, the company said.
XenoPort should stop spending limited resources on a drug that, while active, appears to be inferior to the standard of care in psoriasis, Cowen & Co analyst Eric Schmidt wrote in a note.
The drug's profile compares poorly to Celegene Corp's Otezla, which was approved last year for psoriasis, and Biogen Inc's multiple sclerosis drug Tecfidera, the analyst said.
The company said gastrointestinal events, which also included nausea, abdominal pain and vomiting, were the most frequent side effects.
XenoPort, however, said it expected to start late-stage trials next year and that it would explore partnerships to speed up the development of the oral drug globally.
Psoriasis, one of the most prevalent yet difficult-to-treat autoimmune diseases, causes itchy or sore patches of thick, red skin with silvery scales.
The disease is estimated to affect 2.0-2.6 percent of the U.S. population, with higher incidence in Caucasians, according to the National Institutes of Health.
About 15 percent of psoriasis patients may eventually develop psoriasis arthritis, a debilitating joint condition.
XenoPort said both 800 mg and 400 mg doses of the drug reduced the severity of psoriasis.
The U.S. Food and Drug Administration earlier this year approved Novartis' injectable drug, Cosentyx, for treating psoriasis. Eli Lilly & Co is also developing Ixekizumab for treating the disease.
Canada's Valeant Pharmaceuticals International Inc also bought rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.
The company shares fell 25 percent to their year low of $5 in mid-day trade on the Nasdaq.
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Saumyadeb Chakrabarty and Anil D'Silva)
[a_keyword] => [a_wordcount] => 360 [a_note] => [a_published] => 1 [a_updated] => 0 [a_writtenTime] => 2015-09-15 14:02:11 [a_submittedTime] => 2015-09-15 14:02:11 [a_modifiedTime] => 2015-09-15 14:04:38 [a_publishedTime] => 2015-09-15 14:02:11 [a_editor] => 1 [a_closeComment] => 1 [a_level] => 3 [a_social] => XenoPort's Psoriasis Drug Shows Higher Side Effects; Shares Fall [a_commission] => 0 [a_countDown] => [a_countDownText] => [link] => https://www.medicaldaily.com/xenoports-psoriasis-drug-shows-higher-side-effects-shares-fall-352606 [c_type] => 1 [c_name] => Innovation [c_slug] => innovation [c_ancestry] => -35674- [c_ancestry_slug] => [c_parent_id] => 0 [x_id] => 0 [c_text] =>Technology & the Business of Medicine
[c_iab] => [c_order] => 0 [c_allow] => 1 [c_time] => 0000-00-00 00:00:00 [c_country] => [tid] => 35674 [c_parent] => Array ( [0] => 35674 ) [c_path] => Array ( [0] => Innovation ) [c_status] => Array ( [0] => 1 ) [c_path_slug] => Array ( [0] => innovation ) [w] => [h] => [categories] => Array ( [0] => Array ( [c_id] => 35674 [c_type] => 1 [c_name] => Innovation [c_slug] => innovation [c_ancestry] => -35674- [c_ancestry_slug] => [c_parent_id] => 0 [x_id] => 0 [c_text] =>Technology & the Business of Medicine
[c_iab] => [c_order] => 0 [c_allow] => 1 [c_time] => 0000-00-00 00:00:00 [c_country] => [tid] => 35674 [c_parent] => Array ( [0] => 35674 ) [c_path] => Array ( [0] => Innovation ) [c_status] => Array ( [0] => 1 ) [c_path_slug] => Array ( [0] => innovation ) [w] => [h] => ) ) [real] => Array ( [ar_id] => 8507 [a_id] => 352606 [r_id] => 894 [ar_num] => 0 [ar_prefix] => [ar_suffix] => [ar_show] => 1 [ar_weight] => 0 [ar_replace] => [id_id] => 0 [r_img_show] => 0 [r_name] => Reuters [r_slug] => reporters/reuters [r_title] => [r_prefix] => [r_suffix] => [r_type] => [r_desc] => [r_email] => thisisnotreal@notreal1.com [r_facebook] => [r_twitter] => [r_linkedin] => [r_country] => [r_team] => 0 [r_nef] => [r_company] => [r_article_count] => 804 [r_aid] => 0 [r_parent_id] => 0 [r_allow] => 1 [r_active] => 0 [cen_r_id] => 0 [r_time] => 2014-09-08 09:04:19 [temp_id] => 0 ) [reporters] => Array ( [0] => Array ( [ar_id] => 8507 [a_id] => 352606 [r_id] => 894 [ar_num] => 0 [ar_prefix] => [ar_suffix] => [ar_show] => 1 [ar_weight] => 0 [ar_replace] => [id_id] => 0 [r_img_show] => 0 [r_name] => Reuters [r_slug] => reporters/reuters [r_title] => [r_prefix] => [r_suffix] => [r_type] => [r_desc] => [r_email] => thisisnotreal@notreal1.com [r_facebook] => [r_twitter] => [r_linkedin] => [r_country] => [r_team] => 0 [r_nef] => [r_company] => [r_article_count] => 804 [r_aid] => 0 [r_parent_id] => 0 [r_allow] => 1 [r_active] => 0 [cen_r_id] => 0 [r_time] => 2014-09-08 09:04:19 [temp_id] => 0 ) ) [reporterAll] => Array ( [0] => Array ( [r_id] => 894 [r_name] => Reuters [r_team] => 0 [r_slug] => reporters/reuters [ar_weight] => 0 ) ) [reviews] => Array ( ) [s_name] => Medical Daily [s_slug] => medical-daily [s_credit] => Published by Medicaldaily.com [web_id] => 0 [s_aid] => 0 [cen_s_id] => 0 [s_url] => [s_order] => 0 [s_photo] => [s_allow] => 1 [a_facebook] => 0 [a_twitter] => 0 [a_plus] => 0 [a_linkedin] => 0 [a_reddit] => 0 [a_views] => 1439 [r_headline] => XenoPort's Psoriasis Drug Shows Higher Side Effects [a_error] => 0 [a_search] => XenoPort's Psoriasis Drug Shows Higher Side Effects; Shares Fall [a_h1] => [a_standout] => 0 [a_standouted] => 0 [a_special] => [a_rshare] => 0 [a_applenews_id] => [a_applenews_revision] => [a_url_slug] => [a_noindex] => 0 [a_link] => [a_syndication] => 1 [a_meta_description] => [a_key_points] => [a_tier] => [a_value1] => [a_value2] => 0 [a_weight] => 0 [a_whitelist] => 1 [a_permanant_whitelist] => 0 [a_parent_id] => 0 [a_web_id] => 0 [a_rank] => 0 [a_ads] => 1 [a_google_ai] => 0 [a_disclaimer] => 1 [a_cloudsearch] => 0 [a_json] => [keywords] => Array ( [0] => Array ( [k_id] => 5968 [k_keyword] => Psoriasis [k_page_title] => [k_meta_description] => [k_slug] => psoriasis [k_type] => 0 [id_id] => [file_id] => 0 [c_id] => 0 [m_id] => 1 [k_text] => [k_tree] => 5968 [k_parent_id] => 0 [k_ancestry] => -5968- [k_level] => 0 [k_article] => 34 [k_allow] => 2 [k_time] => 2010-07-23 08:31:24 [k_photo] => [k_tid] => 26558 [k_tslug] => conditions/psoriasis [k_approved] => 0 ) [1] => Array ( [k_id] => 5692 [k_keyword] => Dermatological Disorders [k_page_title] => [k_meta_description] => Dermatology is the branch of medicine dealing with the skin and its diseases, a unique specialty with both medical and surgical aspects. A dermatologist takes care of diseases, in the widest sense, and some cosmetic problems of the skin, scalp, hair, and [k_slug] => dermatological-disorders [k_type] => 0 [id_id] => [file_id] => 0 [c_id] => 0 [m_id] => 1 [k_text] => Dermatology is the branch of medicine dealing with the skin and its diseases, a unique specialty with both medical and surgical aspects. A dermatologist takes care of diseases, in the widest sense, and some cosmetic problems of the skin, scalp, hair, and nails. [k_tree] => 5692 [k_parent_id] => 0 [k_ancestry] => -5692- [k_level] => 0 [k_article] => [k_allow] => 2 [k_time] => 2018-02-26 23:14:31 [k_photo] => [k_tid] => 26595 [k_tslug] => conditions/skin-care-dermatology [k_approved] => 0 ) ) [shorten] => [locations] => Array ( ) [related] => Array ( ) [channels] => Array ( ) [graphic] => Array ( ) [feature] => Array ( ) [topics] => Array ( [0] => Array ( [k_id] => 5968 [k_keyword] => Psoriasis [k_page_title] => [k_meta_description] => [k_slug] => psoriasis [k_type] => 0 [id_id] => [file_id] => 0 [c_id] => 0 [m_id] => 1 [k_text] => [k_tree] => 5968 [k_parent_id] => 0 [k_ancestry] => -5968- [k_level] => 0 [k_article] => 34 [k_allow] => 2 [k_time] => 2010-07-23 08:31:24 [k_photo] => [k_tid] => 26558 [k_tslug] => conditions/psoriasis [k_approved] => 0 [k_count] => 34 ) [1] => Array ( [k_id] => 5692 [k_keyword] => Dermatological Disorders [k_page_title] => [k_meta_description] => Dermatology is the branch of medicine dealing with the skin and its diseases, a unique specialty with both medical and surgical aspects. A dermatologist takes care of diseases, in the widest sense, and some cosmetic problems of the skin, scalp, hair, and [k_slug] => dermatological-disorders [k_type] => 0 [id_id] => [file_id] => 0 [c_id] => 0 [m_id] => 1 [k_text] => Dermatology is the branch of medicine dealing with the skin and its diseases, a unique specialty with both medical and surgical aspects. A dermatologist takes care of diseases, in the widest sense, and some cosmetic problems of the skin, scalp, hair, and nails. [k_tree] => 5692 [k_parent_id] => 0 [k_ancestry] => -5692- [k_level] => 0 [k_article] => [k_allow] => 2 [k_time] => 2018-02-26 23:14:31 [k_photo] => [k_tid] => 26595 [k_tslug] => conditions/skin-care-dermatology [k_approved] => 0 [k_count] => 347 ) ) [first_info] => Array ( [eh_id] => 16954 [eh_what] => article [a_id] => 352606 [eh_type] => imageBox [eh_align] => block [eh_width] => 736 [eh_height] => [eh_w] => 736 [eh_h] => 0 [eh_position] => -2 [eh_text] => [eh_parent] => 0 [eh_num] => 0 [eh_time] => 2015-09-15 14:02:11 [eh_x1] => 352610 [eh_d1] => 352610 [eh_d2] => [eh_d3] => Publix Supermarket pharmacy manager counts out the correct number of antibiotic pills to fill a prescription August 7, 2007 in Miami, Florida. [eh_d4] => [eh_d5] => GettyImages-76008514 [eh_d6] => [eh_d7] => [eh_d8] => [eh_d9] => [eh_d10] => [eh_d11] => ) [review_item] => Array ( ) [a_content_first] => [a_content] =>(Reuters) - XenoPort Inc's psoriasis drug showed high rates of gastrointestinal-related side effects, overshadowing its success in a mid-stage study.
The company's shares, which rose as much as 19 percent premarket, fell sharply in regular trading after the company said on a conference call that a third of its patients in the study dropped out due to the side effects.
During the trial of the drug, XP23829, in patients suffering from the chronic skin disease, adverse events related to diarrhea were 22-40 percent in the drug group, compared with 15 percent in the placebo group, the company said.
XenoPort should stop spending limited resources on a drug that, while active, appears to be inferior to the standard of care in psoriasis, Cowen & Co analyst Eric Schmidt wrote in a note.
The drug's profile compares poorly to Celegene Corp's Otezla, which was approved last year for psoriasis, and Biogen Inc's multiple sclerosis drug Tecfidera, the analyst said.
The company said gastrointestinal events, which also included nausea, abdominal pain and vomiting, were the most frequent side effects.
XenoPort, however, said it expected to start late-stage trials next year and that it would explore partnerships to speed up the development of the oral drug globally.
Psoriasis, one of the most prevalent yet difficult-to-treat autoimmune diseases, causes itchy or sore patches of thick, red skin with silvery scales.
The disease is estimated to affect 2.0-2.6 percent of the U.S. population, with higher incidence in Caucasians, according to the National Institutes of Health.
About 15 percent of psoriasis patients may eventually develop psoriasis arthritis, a debilitating joint condition.
XenoPort said both 800 mg and 400 mg doses of the drug reduced the severity of psoriasis.
The U.S. Food and Drug Administration earlier this year approved Novartis' injectable drug, Cosentyx, for treating psoriasis. Eli Lilly & Co is also developing Ixekizumab for treating the disease.
Canada's Valeant Pharmaceuticals International Inc also bought rights to AstraZeneca Plc's late-stage experimental psoriasis drug brodalumab after it was dropped by Amgen Inc in May.
The company shares fell 25 percent to their year low of $5 in mid-day trade on the Nasdaq.
(Reporting by Anjali Rao Koppala in Bengaluru; Editing by Saumyadeb Chakrabarty and Anil D'Silva)
[a_content_last] => [a_aside] => [a_content_first_type] => imageBox [a_content_last_type] => [a_content_embed] => [reps] => Array ( [0] => Reuters ) [repid] => Array ( [0] => 894 ) [image] => Array ( [id_id] => 352610 [id_name] => GettyImages-76008514 [id_caption] => Publix Supermarket pharmacy manager counts out the correct number of antibiotic pills to fill a prescription August 7, 2007 in Miami, Florida. [id_short_caption] => [id_credit] => Joe Raedle/Getty Images [id_keyword] => [id_gallery] => [id_adult] => 0 [id_hide] => 0 [id_source] => [id_photographer] => [id_text] => [id_ext] => jpg [id_location] => [id_width] => 2500 [id_height] => 1667 [id_left] => 50 [id_top] => 40 [id_quality] => 85 [id_filesize] => 497315 [s_id] => [m_id] => 812 [x_id] => 0 [id_time] => 2015-09-15 14:13:13 [id_submittedTime] => 2015-09-15 14:13:13 [id_url] => [id_published] => 1 [img_name] => public://2015/09/15/gettyimages-76008514.jpg [ori] => https://d.medicaldaily.com/en/full/352610/gettyimages-76008514.jpg [src] => https://d.medicaldaily.com/en/full/352610/gettyimages-76008514.jpg [tag] => src="https://d.medicaldaily.com/en/full/352610/gettyimages-76008514.jpg" alt="GettyImages-76008514" [picture] =>